Renovaro BioSciences announces publication of study on dendritic cell therapy

Renovaro Biosciences (RENB) announced the publication of a peer-reviewed study in Vaccines. The paper details preclinical data on Renovaro’s next-generation dendritic cell therapy platform, showcasing its ability to significantly reduce pancreatic tumor burden and activate robust immune responses in humanized mouse models. The published study, titled “Therapeutic Efficacy of CD34-derived Allogeneic Dendritic Cells Engineered to Express CD93, CD40L, and CXCL13 in Humanized Mouse Models of Pancreatic Cancer,” represents a major milestone in validating the scientific underpinnings of Renovaro’s platform. The therapy combines cutting-edge genetic engineering with an allogeneic “off-the-shelf” approach to generate highly potent DCs capable of priming the immune system against aggressive, immunoresistant tumors. Key Findings from the Study Include: Engineered DCs expressing CD93, CD40L, and CXCL13 significantly reduced tumor weight and volume, namely up to 81.7% in humanized mouse models. Treated animals showed marked increases in CD4 T cells as well as cytotoxic CD8 T and NK cells in blood, bone marrow, and tumor microenvironments. Activated T cells demonstrated selective cytotoxicity against pancreatic tumor cells while sparing unrelated cell types. The use of CD34 hematopoietic stem cells from healthy donors enables scalable production and cryopreservation of engineered DCs, enhancing clinical utility.